JP2023504620A5 - - Google Patents

Info

Publication number
JP2023504620A5
JP2023504620A5 JP2022532732A JP2022532732A JP2023504620A5 JP 2023504620 A5 JP2023504620 A5 JP 2023504620A5 JP 2022532732 A JP2022532732 A JP 2022532732A JP 2022532732 A JP2022532732 A JP 2022532732A JP 2023504620 A5 JP2023504620 A5 JP 2023504620A5
Authority
JP
Japan
Prior art keywords
seq
oxmif
antibody according
antibody
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022532732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/084676 external-priority patent/WO2021110935A1/en
Publication of JP2023504620A publication Critical patent/JP2023504620A/ja
Publication of JP2023504620A5 publication Critical patent/JP2023504620A5/ja
Withdrawn legal-status Critical Current

Links

JP2022532732A 2019-12-06 2020-12-04 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物 Withdrawn JP2023504620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214037 2019-12-06
EP19214037.4 2019-12-06
PCT/EP2020/084676 WO2021110935A1 (en) 2019-12-06 2020-12-04 Anti-oxMIF/anti-CD3 BISPECIFIC ANTIBODY CONSTRUCTS

Publications (2)

Publication Number Publication Date
JP2023504620A JP2023504620A (ja) 2023-02-06
JP2023504620A5 true JP2023504620A5 (https=) 2023-12-11

Family

ID=68808117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022532732A Withdrawn JP2023504620A (ja) 2019-12-06 2020-12-04 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物

Country Status (8)

Country Link
US (1) US20230045873A1 (https=)
EP (1) EP4069735A1 (https=)
JP (1) JP2023504620A (https=)
KR (1) KR20220110221A (https=)
CN (1) CN115943160A (https=)
AU (1) AU2020397229A1 (https=)
CA (1) CA3161783A1 (https=)
WO (1) WO2021110935A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220521A1 (en) 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies
US9958456B2 (en) * 2011-10-07 2018-05-01 Baxalta Incorporated OxMIF as a diagnostic marker
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
RU2639287C2 (ru) * 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3802595A1 (en) 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
TWI899079B (zh) * 2019-05-23 2025-10-01 美商維洛斯生物公司 抗ror1/抗cd3雙特異性結合分子
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子

Similar Documents

Publication Publication Date Title
US11866785B2 (en) Tumor specific antibodies and T-cell receptors and methods of identifying the same
JP2023504620A5 (https=)
JP2020534830A5 (https=)
US20230074705A1 (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
CN118652334B (zh) 一种靶向钙粘蛋白17的纳米抗体及其应用
Li et al. Characterization and humanization of VNARs targeting human serum albumin from the whitespotted bamboo shark (Chiloscyllium plagiosum)
CN117430709B (zh) 一种纳米抗体及其应用
CA3182339A1 (en) Synthetic single domain library
CN120535638B (zh) 一种抗泛赖氨酰氧化酶家族纳米抗体或抗原结合片段与应用
CN120518770B (zh) 一种抗loxl2纳米抗体或抗原结合片段与应用
CN106854246B (zh) 一种针对pi3k的纳米抗体及其临床应用
CN117534763B (zh) 抗bcma的纳米抗体及其制备方法与应用
CN119285786B (zh) 一种抗fap的纳米抗体及其应用
US20140296491A1 (en) Generating metal ion binding proteins
CN117886939A (zh) 一组抗bcma的纳米抗体及其应用
HK40040607B (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
HK40040607A (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
CN112851815A (zh) 抗bcma抗体或其抗原结合片段及其制备方法和应用
Park mRNA Display selection of a novel activated leukocyte cell adhesion molecule (ALCAM) binding protein from a modified combinatorial protein library based on the tenth domain of human fibronection III (10FnIII)
HK1218779B (en) Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes